Very high frequency of the polymorphism for the insulin receptor substrate 1 (IRS-1) at codon 972 (Glycine972Arginine) in Southern Italian women with polycystic ovary syndrome

Hormone and Metabolic Research

Volumn 42, Issue 8, 2010, Pages 575-584

  Pappalardo, M A ^a   Russo, G T ^a   Pedone, A ^a   Pizzo, A ^a   Borrielli, I ^a   Stabile, G ^a   Artenisio, A C ^a   Amato, A ^b   Calvani, M ^b   Cucinotta, D ^a   Trimarchi, F ^a   Benvenga, S ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

hyperandrogenism; insulin resistance; single nucleotide polymorphisms

Indexed keywords

GENOMIC DNA; INSULIN RECEPTOR SUBSTRATE 1; CODON; INSULIN RECEPTOR SUBSTRATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CODON; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA POLYMORPHISM; ECHOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; ITALY; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UNIVERSITY HOSPITAL; WILD TYPE; BLOOD; BODY MASS; CASE CONTROL STUDY; GENETIC ASSOCIATION; GENETICS; HETEROZYGOTE; OVARY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

BODY MASS INDEX; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; ITALY; OVARY; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES; YOUNG ADULT;

EID: 77954226567     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1249020     Document Type: Article

References (36)

1. Nestler JE. Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 1998 70 811-812
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United Stated: a prospective study. J Clin Endocrinol Metab 1998 83 3078-3082
3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999 84 4006-4011
4. Asuncin M, Calvo RM, San Milln JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000 85 2434-2438
5. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reprod Update 2003 6 505-514
6. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A Givens JR Haseltine FP Merriam GR eds. Polycycistic ovary syndrome Boston Blackwell Scientific Publication 1992 377-384
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 81 19-25
8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen Excess Society guideline. J Clin Endocrinol Metab 2006 91 4237-4245
9. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006 185 227-239
10. Cussons AJ, Stuckey BG, Watts GF. Metabolic syndrome and cardiometabolic risk in PCOS. Curr Diabetes Rep 2007 7 66-73
11. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003 52 908-915
12. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007 370 685-697
13. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulation hormone and leuteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996 81 302-309
14. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002 87 2128-2133
15. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jörvinen H, Karonen SL, Seppölö M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988 66 266-272
16. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998 138 269-274
17. Bayram F, Unluhizarci K, Kelestimur F. Potential utility of insulin sensitizers in the treatment of patients with Polycystic ovary syndrome. Treat Endocrinol 2002 1 45-53
18. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994 265 2037-2048
19. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003 46 990-995
20. Sesti G. Insulin receptor substrate polymorphism and type 2 diabetes mellitus. Pharmacogenomics 2001 1 343-357
21. Happ M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, Wallwiener D, Stumvoll M, Höring H-U, Fritsche A. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2005 113 275-281
22. El Mkadem SA, Lautier C, Macari F, Molinari N, Lefèbvre P, Renard E, Gris JC, Cros G, Daurès JP, Bringer J, White MF, Grigorescu F. Role of allelic variant Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001 50 2164-2168
23. Villuendas G, Botella-Carretero JI, Roldán B, Sancho J, Escobar-Morreale HF, San Millán JL. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod 2005 20 3184-3191
24. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril 2005 84 407-412
25. Sir-Petermann T, Angel B, Maliqueo M, Santos JL, Riesco MV, Toloza H, Pérez-Bravo F. Insulin secretion in women who have polycystic ovary syndrome and carry Gly972Arg variant of insulin receptor substrate-1 in response to a high-glycemic or low-glycemic carbohydrate load. Nutrition 2004 20 905-910
26. Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clin Chim Acta 2008 390 63-66
27. Baba T, Endo T, Sata F, Homma H, Kitajima Y, Manase K, Kanaya M, Yamada H, Minatami H, Kishi R, Saito T. Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in Japanese population. Life Sci 2007 81 850-854
28. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and 2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002 87 4297-4300
29. Lin TC, Yen JM, Gong KB, Kuo TC, Ku DC, Liang SF, Wu MJ. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet 2006 7 2350-2370
30. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995 96 520-527
31. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998 95 14956-14960
32. Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000 13 1303-1306
33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165-1174
34. Corboulda A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signalling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006 55 751-759
35. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices of accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004 89 1273-1276
36. Berga SL. Polycystic ovary syndrome: a model of combinatorial endocrinology? J Clin Endocrinol Metab 2009 94 2250-2251